Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future

The past decade has witnessed major breakthroughs in cancer immunotherapy. This development has been largely motivated by cancer cell evasion of immunological control and consequent tumor resistance to conventional therapies. Immunogenic cell death (ICD) is considered one of the most promising ways...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Razan Alzeibak, Tatiana A. Mishchenko, Natalia Y. Shilyagina, Irina V. Balalaeva, Maria V. Vedunova, Dmitri V. Krysko
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/13aa155c3306436198a2ed95ed7f104a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:13aa155c3306436198a2ed95ed7f104a
record_format	dspace
spelling	oai:doaj.org-article:13aa155c3306436198a2ed95ed7f104a2021-11-16T07:00:05ZTargeting immunogenic cancer cell death by photodynamic therapy: past, present and future10.1136/jitc-2020-0019262051-1426https://doaj.org/article/13aa155c3306436198a2ed95ed7f104a2021-01-01T00:00:00Zhttps://jitc.bmj.com/content/9/1/e001926.fullhttps://doaj.org/toc/2051-1426The past decade has witnessed major breakthroughs in cancer immunotherapy. This development has been largely motivated by cancer cell evasion of immunological control and consequent tumor resistance to conventional therapies. Immunogenic cell death (ICD) is considered one of the most promising ways to achieve total tumor cell elimination. It activates the T-cell adaptive immune response and results in the formation of long-term immunological memory. ICD can be triggered by many anticancer treatment modalities, including photodynamic therapy (PDT). In this review, we first discuss the role of PDT based on several classes of photosensitizers, including porphyrins and non-porphyrins, and critically evaluate their potential role in ICD induction. We emphasize the emerging trend of ICD induction by PDT in combination with nanotechnology, which represents third-generation photosensitizers and involves targeted induction of ICD by PDT. However, PDT also has some limitations, including the reduced efficiency of ICD induction in the hypoxic tumor microenvironment. Therefore, we critically evaluate strategies for overcoming this limitation, which is essential for increasing PDT efficiency. In the final part, we suggest several areas for future research for personalized cancer immunotherapy, including strategies based on oxygen-boosted PDT and nanoparticles. In conclusion, the insights from the last several years increasingly support the idea that PDT is a powerful strategy for inducing ICD in experimental cancer therapy. However, most studies have focused on mouse models, but it is necessary to validate this strategy in clinical settings, which will be a challenging research area in the future.Razan AlzeibakTatiana A. MishchenkoNatalia Y. ShilyaginaIrina V. BalalaevaMaria V. VedunovaDmitri V. KryskoBMJ Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Razan Alzeibak Tatiana A. Mishchenko Natalia Y. Shilyagina Irina V. Balalaeva Maria V. Vedunova Dmitri V. Krysko Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
description	The past decade has witnessed major breakthroughs in cancer immunotherapy. This development has been largely motivated by cancer cell evasion of immunological control and consequent tumor resistance to conventional therapies. Immunogenic cell death (ICD) is considered one of the most promising ways to achieve total tumor cell elimination. It activates the T-cell adaptive immune response and results in the formation of long-term immunological memory. ICD can be triggered by many anticancer treatment modalities, including photodynamic therapy (PDT). In this review, we first discuss the role of PDT based on several classes of photosensitizers, including porphyrins and non-porphyrins, and critically evaluate their potential role in ICD induction. We emphasize the emerging trend of ICD induction by PDT in combination with nanotechnology, which represents third-generation photosensitizers and involves targeted induction of ICD by PDT. However, PDT also has some limitations, including the reduced efficiency of ICD induction in the hypoxic tumor microenvironment. Therefore, we critically evaluate strategies for overcoming this limitation, which is essential for increasing PDT efficiency. In the final part, we suggest several areas for future research for personalized cancer immunotherapy, including strategies based on oxygen-boosted PDT and nanoparticles. In conclusion, the insights from the last several years increasingly support the idea that PDT is a powerful strategy for inducing ICD in experimental cancer therapy. However, most studies have focused on mouse models, but it is necessary to validate this strategy in clinical settings, which will be a challenging research area in the future.
format	article
author	Razan Alzeibak Tatiana A. Mishchenko Natalia Y. Shilyagina Irina V. Balalaeva Maria V. Vedunova Dmitri V. Krysko
author_facet	Razan Alzeibak Tatiana A. Mishchenko Natalia Y. Shilyagina Irina V. Balalaeva Maria V. Vedunova Dmitri V. Krysko
author_sort	Razan Alzeibak
title	Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
title_short	Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
title_full	Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
title_fullStr	Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
title_full_unstemmed	Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
title_sort	targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/13aa155c3306436198a2ed95ed7f104a
work_keys_str_mv	AT razanalzeibak targetingimmunogeniccancercelldeathbyphotodynamictherapypastpresentandfuture AT tatianaamishchenko targetingimmunogeniccancercelldeathbyphotodynamictherapypastpresentandfuture AT nataliayshilyagina targetingimmunogeniccancercelldeathbyphotodynamictherapypastpresentandfuture AT irinavbalalaeva targetingimmunogeniccancercelldeathbyphotodynamictherapypastpresentandfuture AT mariavvedunova targetingimmunogeniccancercelldeathbyphotodynamictherapypastpresentandfuture AT dmitrivkrysko targetingimmunogeniccancercelldeathbyphotodynamictherapypastpresentandfuture
_version_	1718426649726287872

Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future

Ejemplares similares